Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTORNASDAQ:IMABNASDAQ:MDCXNASDAQ:ME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTORCitius Oncology$2.50-4.9%$1.02$0.55▼$4.42$188.18M-0.071.17 million shs1.92 million shsIMABI-Mab$2.46-1.6%$1.38$0.60▼$3.08$204.15M1.17361,980 shs354,719 shsMDCXMedicus Pharma$2.34-6.0%$4.21$1.80▼$8.94$33.80MN/A400,333 shs172,966 shsME23andMe$0.50-35.3%$0.50$0.53▼$10.81$13.36M1.191.42 million shs29.28 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTORCitius Oncology-4.94%+79.86%+174.73%+214.86%+249,999,900.00%IMABI-Mab-1.60%-2.38%+148.48%+182.66%+46.43%MDCXMedicus Pharma-6.02%-12.03%-67.90%-27.10%+233,999,900.00%ME23andMe0.00%0.00%0.00%-23.38%-94.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTORCitius Oncology0.3934 of 5 stars2.00.00.00.00.01.70.0IMABI-Mab2.5934 of 5 stars3.74.00.00.00.61.70.6MDCXMedicus Pharma1.2141 of 5 stars3.80.00.00.00.00.80.0ME23andMeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTORCitius Oncology 2.00Hold$3.0020.00% UpsideIMABI-Mab 3.33Buy$5.50123.58% UpsideMDCXMedicus Pharma 3.50Strong Buy$23.50904.27% UpsideME23andMe 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ME, MDCX, CTOR, and IMAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.006/9/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.005/29/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.005/23/2025CTORCitius OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/23/2025CTORCitius OncologyMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.005/12/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $27.005/8/2025MDCXMedicus PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $20.004/28/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/21/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/14/2025MDCXMedicus PharmaD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTORCitius OncologyN/AN/AN/AN/A$0.64 per shareN/AIMABI-Mab$3.89M51.64N/AN/A$2.47 per share1.00MDCXMedicus PharmaN/AN/AN/AN/A$0.29 per shareN/AME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTORCitius OncologyN/AN/A0.00∞N/AN/A-53.88%-18.86%N/AIMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)MDCXMedicus Pharma-$11.16M-$1.16N/AN/AN/AN/A-380.03%-224.22%6/27/2025 (Estimated)ME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ALatest ME, MDCX, CTOR, and IMAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025CTORCitius Oncology-$0.09-$0.11-$0.02-$0.11$5.74 millionN/A5/12/2025Q1 2025MDCXMedicus Pharma-$0.23-$0.42-$0.19-$0.42N/AN/A3/28/2025Q4 2024MDCXMedicus Pharma-$0.32-$0.18+$0.14-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTORCitius OncologyN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTORCitius Oncology0.110.360.05IMABI-MabN/A22.3522.35MDCXMedicus PharmaN/A1.531.53ME23andMeN/A1.050.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTORCitius Oncology70.52%IMABI-Mab38.38%MDCXMedicus PharmaN/AME23andMe36.10%Insider OwnershipCompanyInsider OwnershipCTORCitius Oncology4.57%IMABI-Mab22.10%MDCXMedicus PharmaN/AME23andMe26.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTORCitius OncologyN/A71.55 million68.28 millionN/AIMABI-Mab38081.66 million63.61 millionOptionableMDCXMedicus PharmaN/A13.57 millionN/AN/AME23andMe77026.83 million19.77 millionNot OptionableME, MDCX, CTOR, and IMAB HeadlinesRecent News About These CompaniesVenture Firm Plans $10 Million Bid for 23andMe Health-Care UnitJune 24 at 1:28 AM | news.bloomberglaw.comBidder emerges for 23andMe's Lemonaid Health unitJune 24 at 1:28 AM | bizjournals.comCan 23andMe sell customers' DNA data? Bankruptcy hearing continued FridayJune 20, 2025 | stltoday.com23andMe Bankruptcy Judge to Rule Soon on Genetic Data Asset SaleJune 20, 2025 | news.bloomberglaw.comThe Score: 23andMe, U.S. Steel, Accenture and More Stocks That Defined the WeekJune 20, 2025 | wsj.com23andMe’s ex-CEO is trying to buy the company. A St. Louis judge could decide Friday.June 20, 2025 | stltoday.comICO Imposes 2.31 Million Pound Fine on 23andMeJune 19, 2025 | govinfosecurity.com23andMe Could Owe You Up to $10,000 After Its Data Breach SettlementJune 19, 2025 | cnet.com23andMe Bankruptcy Judge Rejects Texas Effort to Halt Data SaleJune 18, 2025 | news.bloomberglaw.comBattle for 23andMe (and its data) growsJune 18, 2025 | finance.yahoo.comGene data: British data protection fine for 23andmeJune 18, 2025 | heise.deOklahoma files federal lawsuit against 23andMeJune 17, 2025 | kgou.org23andMe fined millions by watchdog after ‘profoundly damaging’ cyber attack exposing genetic dataJune 17, 2025 | lbc.co.ukUK Watchdogs Fine 23andMe $3.1M for Data Security ViolationsJune 17, 2025 | msn.comAnne Wojcicki on genetic privacy, data security and the money behind her bid for 23andMeJune 17, 2025 | bizjournals.com23andMe co-founder wins bid to take back control of companyJune 17, 2025 | massdevice.comICO fines bankrupt 23andMe £2.3m for massive privacy breachJune 17, 2025 | sharecast.comAnne Wojcicki wins bid to buy back 23andMe for $305MJune 17, 2025 | medtechdive.comUK regulator fines 23andMe over massive genetic data breachJune 17, 2025 | biometricupdate.com23andMe co-founder Anne Wojcicki regains control of bankrupt genetic testing companyJune 17, 2025 | msn.comOne Tech Tip: How to protect your 23andMe genetic dataJune 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyME, MDCX, CTOR, and IMAB Company DescriptionsCitius Oncology NASDAQ:CTOR$2.50 -0.13 (-4.94%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$2.67 +0.17 (+6.80%) As of 05:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.I-Mab NASDAQ:IMAB$2.46 -0.04 (-1.60%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$2.45 -0.01 (-0.57%) As of 04:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.Medicus Pharma NASDAQ:MDCX$2.34 -0.15 (-6.02%) As of 06/23/2025 04:00 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.23andMe NASDAQ:ME$0.50 -0.27 (-35.32%) Closing price 03/28/2025Extended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
